Pfizer Inc. (NYSE:PFE) is beginning to show signs of steadier growth following the sharp decline in its pandemic-related ...

Pfizer is facing material patent expirations over the next two years, but that will be over by 2030.

The next few years will test whether Pfizer Inc. (NYSE:PFE) can replace yesterday’s blockbusters, and whether Gilead Sciences ...

Pfizer Inc PFE shares are trading higher Wednesday, moving in sympathy with mRNA cancer vaccine-related companies after Merck & Co Inc MRK and Moderna Inc MRNA announced that their combination therapy ...

Pfizer's dividend yield is 7% for a very good reason: investors are worried about the risk of a dividend cut.

A biomanufacturing facility in Everett that Pfizer decided to shut down before it opened is getting a new lease on life, with ...

Stocks that don't generate strong returns can still make good dividend investments. As long as their payouts are sustainable ...

Shares of global pharmaceutical company Pfizer (NYSE:PFE) jumped 3.8% in the afternoon session after positive clinical trial ...

Pfizer's $31 billion bond sale ranks among the largest ever, but it's still only half the size, adjusted for inflation, of ...

Pfizer's cardiovascular business highlights the intersection of drug pricing, marketing, patents, and competition in the ...

Pfizer, Chevron, and AbbVie have already rewarded dividend investors with strong 2026 gains, but the bull case for 2027 ...

The submission is supported by efficacy and safety data from the Phase III VALOR clinical trial.